Retention rate and predictor factors of drug discontinuation in axial spondyloarthritis: a focus on certolizumab and secukinumab. Reumatismo, [S. l.], 2025. DOI: 10.4081/reumatismo.2025.1792. Disponível em: https://www.reumatismo.org/reuma/article/view/1792. Acesso em: 27 jun. 2025.